CLDN18 is a cell surface membrane protein involved in the formation of tight junctions, and the expression of its CLDN18.2 isoform has been observed in pancreatic, gastric and esophageal tumors.
Researchers from Nkgen Biotech Inc. have developed an anti-HER2 CAR NK cell therapy, named SNK-02, as a potential immunotherapeutic for HER2-overexpressing tumors. SNK-02 was tested in a xenografted murine model of cancer.
Researchers from Adicet Bio Inc. reported on the preclinical development of ADI-925, an engineered Chimeric Adapter (CAd) γδ1 T-cell therapy that targets major histocompatibility complex class I chain-related protein A/B (MICA/MICB) and ULBP1-6 expressed in tumor cells.
Certain types of human papillomavirus (HPV), named high-risk types, are known to be clearly associated with 60% of invasive cervical cancer cases. Prophylactic HPV vaccines are highly effective, but there is a need for new treatment options other than surgery.
Researchers from Tscan Therapeutics Inc. presented preclinical data for TSC-200-A0201, a naturally occurring HPV16 E7-specific T-cell receptor (TCR) T-cell therapy discovered using Tscan’s proprietary Receptorscan platform. It is being developed for the treatment of human papillomavirus 16 (HPV16)-positive solid tumors. The therapeutic TCR in TSC-200-A0201 was introduced into a transposon vector, with the resulting TCR T therapy product being a mixture of cytotoxic and helper T cells, both reprogrammed to recognize HPV16+ HLA-A*02:01+ cells.
Protein tyrosine kinase 7 (PTK7) is a pseudo tyrosine kinase overexpressed in many cancer types such as ovarian, triple-negative breast cancer (TNBC), non-small-cell lung cancer, small-cell lung cancer and bladder cancer, but limited expression in normal tissues.
Researchers from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. and Doma Biopharmaceutical (Suzhou) Co. Ltd. reported the discovery and preclinical data of DM-005, a novel fully human EGFR × MET bispecific antibody-drug conjugate (ADC) being developed for the treatment of cancer.
KLRG1 is expressed on a subset of T and NK cells, with KLRG1+CD8+ T cells having demonstrated strong antitumor cytotoxicity by releasing IFN-γ and TNF-α.
Researchers from Chugai Pharmaceutical Co. Ltd. presented preclinical data of SAIL-66, a trispecific antibody targeting Claudin-6 (CLDN6), CD137 (4-1BB) and CD3, for cancer immunotherapy.
Researchers from Umoja Biopharma Inc. presented the discovery and preclinical evaluation of UB-VV200, a third-generation lentiviral vector containing a multi-domain fusion (MDF) protein consisting of a T cell-targeting anti-CD3 scFv and costimulatory proteins.
RSS
